ESPR - Company ID 0001434868
Esperion Therapeutics, Inc. trades as ESPR. In its fiscal 2025 annual report the company posted revenue of $403.13M, up 21.3% from the prior year and net income of -$22.68M. This page tracks Esperion Therapeutics, Inc. through 885 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -65.5% to -5.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-08 |
| Proxy materials | DEFA14A | 2026-05-04 |
| Proxy materials | DEFA14A | 2026-05-01 |
| Proxy materials | DEFA14A | 2026-05-01 |
| Major company event | 8-K | 2026-05-01 |
| SCHEDULE 13G | - | 2026-04-22 |
| Annual report to shareholders | ARS | 2026-04-16 |
| Proxy materials | DEFA14A | 2026-04-16 |
The largest companies sharing Esperion Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Esperion Therapeutics, Inc. reported revenue of $403.13M for fiscal year 2025, an increase of 21.3% year over year.
In its latest fiscal year Esperion Therapeutics, Inc. reported a net loss of $22.68M.